Science Letter
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Science Letter
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Non-Hodgkin Lymphoma
Quantitative PET imaging finds early determination of effectiveness of cancer treatment
November 20th, 2007
With positron emission tomography (PET) imaging, seeing is believing: Evaluating a patient’s response to chemotherapy for non-Hodgkin lymphoma (NHL) typically involves visual interpretation of scans of cancer tumors. Researchers have found that measuring a quantitative index—one that reflects the reduction of metabolic activity after chemotherapy first begins—adds accurate information about patients’ responses to first-line chemotherapy, according to a study in the October issue of the Journal of Nuclear Medicine. "In our study, we demonstrated that a quantitative assessment of therapeutic response for patients with diffuse large B-cell lymphoma (DLBCL) is more accurate...
Source: Science Letter (2007-11-20)
|
